z-logo
open-access-imgOpen Access
miR-221-3p Delivered by BMMSC-Derived Microvesicles Promotes the Development of Acute Myelocytic Leukemia
Author(s) -
Xuewu Zhang,
Yu Xu,
Jinghan Wang,
Shuqi Zhao,
Jianhu Li,
Xin Huang,
Huan Xu,
Xiang Zhang,
Shanshan Suo,
Yunfei Lv,
Yi Zhang,
Wenjuan Yu
Publication year - 2020
Publication title -
frontiers in bioengineering and biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.081
H-Index - 44
ISSN - 2296-4185
DOI - 10.3389/fbioe.2020.00081
Subject(s) - microvesicles , cell cycle , flow cytometry , biology , cell growth , microbiology and biotechnology , cell , microrna , apoptosis , cancer research , stem cell , immunology , genetics , gene
Objective: The study aims to investigate the effects of miR-221-3p in bone marrow mesenchymal stem cell (BMMSC)-derived microvesicles (MVs) on cell cycle, proliferation and invasion of acute myelocytic leukemia (AML). Methods: Bioinformatics was used to predict differentially expressed miRNAs (DEmiRNAs) in AML. The morphology of BMMSC-derived MVs was observed under an electron microscope, and the positional relation of MVs and OCI-AML2 cells was observed by a fluorescence microscope. MTT, Transwell, and flow cytometry assays were used to analyze the effects of MVs on OCI-AML2 cells. The targeted relationship between miR-221-3p and CDKN1C was detected by dual luciferase assay. Results: It was verified that miR-221-3p promoted the proliferation, invasion and migration of OCI-AML2 cells, and induced the cell cycle arrest in G1/S phase as well as inhibited cell apoptosis. Further studies showed that MVs promoted the proliferation, migration and invasion of AML, and induced the cell cycle arrest in G1/S phase through miR-221-3p. It was confirmed that miR-221-3p can directly target CDKN1C to regulate cell cycle, proliferation and invasion of AML. Conclusion: miR-221-3p in BMMSC-derived MVs regulated AML cell cycle, cell proliferation and invasion through targeting CDKN1C. miR-221-3p and CDKN1C were considered to be potential targets and biomarkers for the treatment of AML in clinic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom